



VGI Health Technology Limited

ABN: 35 111 082 485

Address: c/- Structured Tax & Accounting

Suite 4, 24 Birdwood Lane, Lane Cove NSW 2066

www.vgiht.com | Tel: +61 2 8279 8908

VGI Health Technology Limited enters into new R&D Loan Facility Agreement with TIV Holdings Pty Ltd

Sydney, New South Wales, 29 June 2023 – VGI Health Technology Limited (**NSX:VTL or the Company**) is pleased to announce that it has entered into a new R&D Loan Facility Agreement (**Loan Facility**) with TIV Holdings Pty Ltd (**TIV**). The new Loan Facility will repay the existing loan agreement with Fund Squire Pty Ltd (see the Company's announcement of 13 October 2022).

For more information please contact:

Dr Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Mrs Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:

https://www.nsx.com.au/broker_list_print.asp